The plot thickens while the scope broadens: a holistic view on IL-17 in psoriasis and other inflammatory disorders.

Abstract

Psoriasis is an instructive example highlighting our growing knowledge about pathophysiological functions of interleukin (IL)-17. IL-17A is the predominant isoform implicated in key pathogenic features in this and other chronic inflammatory disorders. Several monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) or its IL-17RC/RA receptor (brodalumab) are currently in late stages of clinical development, where they have shown impressive efficacy. While the eponymous IL-17 has been thought to originate primarily from T helper (Th)17 cells, more recent investigations by several groups suggest that other cell types in psoriatic lesions, such as neutrophils and mast cells, are rich sources of IL-17, thus presumably contributing to the disease process to an as yet underestimated extent. This recent paradigm shift provides a plausible explanation for the rapid and strong efficacy of the novel compounds targeting IL-17 functions in psoriasis and other inflammatory disorders, and provide a more comprehensive view on the complex cytokine network in these conditions.

• Authors: Michael P Schön
• Journal: Experimental dermatology (Exp Dermatol) Vol. 23 Issue 11 Pg. 804-6 (Nov 2014) ISSN: 1600-0625 [Electronic] Denmark
• PMID: 25219805 (Publication Type: Journal Article, Review, Comment)
• Copyright: © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Interleukin-17

Topics

• Animals
• Gene Expression Regulation
• Humans
• Interleukin-17 (immunology)
• Mast Cells (immunology)
• Neutrophils (immunology)
• Psoriasis (immunology)
• T-Lymphocyte Subsets (immunology)